Home/ Stocks/ GNLX

Genelux Corporation Common Stock

GNLX XNAS

$3.11 +0.35 (+12.37%) ▲ 15-min delayed

Open

$2.85

High

$3.20

Low

$2.83

Volume

368.4K

Market Cap

$139.45M

About Genelux Corporation Common Stock

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 26 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-8,928,000	$-0.20
FY 2025	$8.0K	$-32,145,000	$-0.86
Q3 2025	$0	$-7,950,000	$-0.21
Q2 2025	$0	$-7,456,000	$-0.20

Earnings & Analyst Ratings

Next Earnings: Mon, Aug 3, 2026

Calendar →

Related Market News

No specific coverage for GNLX yet. Check out our latest market news or earnings calendar.

Get GNLX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Genelux Corporation Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.